Over the last 7 days, the United States market has risen by 4.0%, contributing to a remarkable 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying good stocks often involves looking for companies that are not only undervalued but also show signs of insider confidence, such as recent buying activity.
|
Name |
PE |
PS |
Discount to Fair Value |
Value Rating |
|---|---|---|---|---|
|
PCB Bancorp |
9.3x |
3.1x |
21.96% |
★★★★★☆ |
|
FirstSun Capital Bancorp |
11.2x |
2.8x |
44.15% |
★★★★★☆ |
|
AVITA Medical |
NA |
2.2x |
47.72% |
★★★★★☆ |
|
1st Source |
11.6x |
4.3x |
45.11% |
★★★★☆☆ |
|
Tennant |
32.4x |
1.2x |
41.10% |
★★★☆☆☆ |
|
Union Bankshares |
10.3x |
2.1x |
21.90% |
★★★☆☆☆ |
|
New Peoples Bankshares |
9.5x |
2.3x |
24.45% |
★★★☆☆☆ |
|
Bank of the James Financial Group |
11.6x |
2.2x |
41.88% |
★★★☆☆☆ |
|
Aldeyra Therapeutics |
NA |
NA |
41.19% |
★★★☆☆☆ |
|
CEVA |
NA |
5.9x |
-38.05% |
★★★☆☆☆ |
We’ll examine a selection from our screener results.
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Citizens Financial Services operates in the community banking sector, focusing on providing financial services and products, with a market capitalization of approximately $0.29 billion.
Operations: The company generates its revenue primarily from community banking, with operating expenses significantly impacting net income. Over recent periods, the net income margin has shown fluctuations, reaching 33.26% in the latest report. General and administrative expenses are a notable component of costs, amounting to $50.10 million recently.
PE: 9.0x
Citizens Financial Services, a smaller player in the U.S. market, recently announced a share repurchase program worth US$15 million through 2029, reflecting insider confidence. The company reported strong performance with net income rising to US$10.48 million for Q4 2025 from US$7.98 million a year ago and basic earnings per share increasing to US$2.19 from US$1.66 over the same period. Despite having a low allowance for bad loans at 85%, its financials suggest potential growth opportunities ahead.
Simply Wall St Value Rating: ★★★★☆☆
Overview: Fidelity D & D Bancorp operates primarily in banking, trust, and financial services with a market capitalization of approximately $0.31 billion.
Operations: The company generates revenue primarily from its Banking, Trust, and Financial Services segment, with the latest reported figure at $91.66 million. Operating expenses are significant, with General & Administrative Expenses accounting for $48.38 million in the most recent period. Notably, the net income margin has shown fluctuations over time, reaching 30.76% in the latest quarter reported.
PE: 9.5x
Fidelity D & D Bancorp, a smaller financial institution, demonstrates potential value with its recent financial performance and strategic leadership changes. Net interest income climbed to US$72.67 million for 2025 from US$61.87 million the previous year, while net income rose to US$28.2 million from US$20.79 million, indicating strong operational results. The appointment of Peter A. Gray as executive VP and chief lending officer could enhance growth strategies in key markets like Lehigh Valley. Additionally, insider confidence is evident through share purchases over recent months, signaling belief in the company’s prospects despite market challenges.
Simply Wall St Value Rating: ★★★★★☆
Overview: Mesa Laboratories specializes in providing quality control products and services across various segments, including clinical genomics, calibration solutions, biopharmaceutical development, and sterilization and disinfection control, with a market cap of approximately $1.23 billion.
Operations: The company generates revenue primarily from four segments: Clinical Genomics, Calibration Solutions, Biopharmaceutical Development, and Sterilization and Disinfection Control. Over recent periods, the gross profit margin has varied between 57.63% and 64.97%. Operating expenses have been substantial across categories such as General & Administrative, Sales & Marketing, and R&D.
PE: 152.5x
Mesa Labs, a company in the life sciences sector, has shown insider confidence with Lead Independent Director Shiraz Ladiwala purchasing 3,500 shares for US$252,805. This move suggests belief in the company’s potential despite its reliance on higher-risk external funding. Recently reporting improved earnings with US$65 million sales and US$3.6 million net income for Q3 2025, Mesa’s leadership transition to Dr. Siddhartha Kadia could steer future growth. Additionally, their DryCal technology gains traction amid regulatory changes, enhancing occupational safety standards.
-
Dive into all 62 of the Undervalued US Small Caps With Insider Buying we have identified here.
-
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St’s portfolio, where intuitive tools await to help optimize your investment outcomes.
-
Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CZFS FDBC and MLAB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com















